| Previous Close | 83.33 |
| Open | 83.34 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 82.74 - 84.03 |
| 52 Week Range | 64.18 - 86.72 |
| Volume | 3,148,723 |
| Avg. Volume | 3,454,231 |
| Market Cap | 87.86B |
| Beta | 0.12 |
| PE Ratio (TTM) | 36.31 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Dividend & Yield | 2.08 (2.54%) |
| Ex-Dividend Date | 2017-08-11 |
| 1y Target Est | N/A |
- Motley Fool•yesterday
AstraZeneca Stock Upgraded: What You Need to Know
Bernstein sees opportunity in a buyout target.
Markit•2 days agoSee what the IHS Markit Score report has to say about Eli Lilly And Co.
Eli Lilly And Co NYSE:LLY
- Barrons.com•8 days ago
[$$] 4 Buys in a Watchful Market
Eli Lilly • LLY-NYSE Long-Term Buy • Price $82.17 on Sept. 12 by Hilliard Lyons At the European Society for Medical Oncology Annual Congress, Lilly presented strong data from a key trial on its cancer drug Abemaciclib. As a reminder to investors, while cross-trial comparisons are difficult to make, the presentation provided physicians and investors the best opportunity to compare Abemaciclib to the other CDK4/6 inhibitors, and we think it can take some market share from competitors in this niche.
